

**INDIA – March 18, 2020** – At Sanofi, our priority is the safety of our consumers, patients, employees, their families and the communities we are engaged with and ensuring the continuous supply of safe and efficacious products.

The World Health Organisation has stated they are not aware of published clinical or population-based data on ibuprofen and the worsening of COVID-19 and based on currently available information, do not recommend against the use of ibuprofen.<sup>[1]</sup>

As very recently stated by several Health Authorities, including [EMA](#), there is currently no scientific evidence establishing a link between ibuprofen and worsening of COVID-19. <sup>[2]</sup>

In line with EU national treatment guidelines, healthcare professionals can continue prescribing NSAIDs (like ibuprofen) for patient use, as per locally approved [product information](#).

Like Health Authorities, Sanofi is monitoring the situation closely and will review any new information that becomes available on this issue in the context of the pandemic.

As per EMA's statement, it should be reminded that when starting treatment for fever or pain in COVID-19, patients and healthcare professionals should consider all available treatment options including paracetamol and NSAIDs. Each medicine has its own benefits and risks which are reflected in its product information.

Healthcare professionals and patients should refer to their country Health Authorities guidance.

All Sanofi products should be taken in accordance with label instructions and in consultation with the healthcare professional..

Please consult your healthcare practitioner if you have any questions about your individual situation or you suspect you may have COVID-19. Please ensure to follow all COVID-19 guidance from local authorities when contacting your healthcare practitioner.

### About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

### Sanofi Media Relations Contact:

---

<sup>[1]</sup> WHO Twitter, 18 March 2020

<sup>[2]</sup> European Medicines Agency, 18 March 2020

Aparna Thomas  
Tel: +91 22 2803 2169  
[aparna.thomas@sanofi.com](mailto:aparna.thomas@sanofi.com)

**Genesis BCW Media Relation Contact**

Naina Siwach  
Tel.: +91 9870402345  
[Naina.Siwach@genesis-bcw.com](mailto:Naina.Siwach@genesis-bcw.com)

**Forward-Looking Statements**

This press statement contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2018. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.